AnaptysBio Statistics

Total Valuation

AnaptysBio has a market cap or net worth of $1.90 billion. The enterprise value is $1.90 billion.

Market Cap	1.90B
Enterprise Value	1.90B

Important Dates

The next estimated earnings date is Friday, May 8, 2026, after market close.

Earnings Date	May 8, 2026
Ex-Dividend Date	n/a

Share Statistics

AnaptysBio has 28.75 million shares outstanding. The number of shares has increased by 1.33% in one year.

Current Share Class	28.75M
Shares Outstanding	28.75M
Shares Change (YoY)	+1.33%
Shares Change (QoQ)	+8.01%
Owned by Insiders (%)	2.93%
Owned by Institutions (%)	65.65%
Float	17.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	56.07
PS Ratio	8.20
Forward PS	15.37
PB Ratio	50.14
P/TBV Ratio	51.72
P/FCF Ratio	98.13
P/OCF Ratio	97.70
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 39.28, with an EV/FCF ratio of 97.06.

EV / Earnings	n/a
EV / Sales	8.11
EV / EBITDA	39.28
EV / EBIT	39.74
EV / FCF	97.06

Financial Position

The company has a current ratio of 9.07, with a Debt / Equity ratio of 7.81.

Current Ratio	9.07
Quick Ratio	8.94
Debt / Equity	7.81
Debt / EBITDA	5.71
Debt / FCF	14.82
Interest Coverage	0.60

Financial Efficiency

Return on equity (ROE) is -24.49% and return on invested capital (ROIC) is 7.79%.

Return on Equity (ROE)	-24.49%
Return on Assets (ROA)	7.06%
Return on Invested Capital (ROIC)	7.79%
Return on Capital Employed (ROCE)	14.70%
Weighted Average Cost of Capital (WACC)	8.48%
Revenue Per Employee	$2.26M
Profits Per Employee	-$127,231
Employee Count	104
Asset Turnover	0.55
Inventory Turnover	n/a

Taxes

In the past 12 months, AnaptysBio has paid $164,000 in taxes.

Income Tax	164,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +217.87% in the last 52 weeks. The beta is 0.41, so AnaptysBio's price volatility has been lower than the market average.

Beta (5Y)	0.41
52-Week Price Change	+217.87%
50-Day Moving Average	60.43
200-Day Moving Average	41.16
Relative Strength Index (RSI)	55.73
Average Volume (20 Days)	687,203

Short Selling Information

The latest short interest is 4.11 million, so 14.28% of the outstanding shares have been sold short.

Short Interest	4.11M
Short Previous Month	4.81M
Short % of Shares Out	14.28%
Short % of Float	23.79%
Short Ratio (days to cover)	6.57

Income Statement

In the last 12 months, AnaptysBio had revenue of $234.60 million and -$13.23 million in losses. Loss per share was -$0.46.

Revenue	234.60M
Gross Profit	98.63M
Operating Income	47.90M
Pretax Income	-13.07M
Net Income	-13.23M
EBITDA	48.46M
EBIT	47.90M
Loss Per Share	-$0.46

Full Income Statement

Balance Sheet

The company has $311.64 million in cash and $290.64 million in debt, giving a net cash position of $21.00 million or $0.73 per share.

Cash & Cash Equivalents	311.64M
Total Debt	290.64M
Net Cash	21.00M
Net Cash Per Share	$0.73
Equity (Book Value)	37.21M
Book Value Per Share	1.33
Working Capital	311.63M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $19.70 million and capital expenditures -$87,000, giving a free cash flow of $19.61 million.

Operating Cash Flow	19.70M
Capital Expenditures	-87,000
Depreciation & Amortization	559,000
Net Borrowing	n/a
Free Cash Flow	19.61M
FCF Per Share	$0.68

Full Cash Flow Statement

Margins

Gross margin is 42.04%, with operating and profit margins of 20.42% and -5.64%.

Gross Margin	42.04%
Operating Margin	20.42%
Pretax Margin	-5.57%
Profit Margin	-5.64%
EBITDA Margin	20.65%
EBIT Margin	20.42%
FCF Margin	8.36%

Dividends & Yields

AnaptysBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.33%
Shareholder Yield	-1.33%
Earnings Yield	-0.69%
FCF Yield	1.02%

Analyst Forecast

The average price target for AnaptysBio is $71.67, which is 8.41% higher than the current price. The consensus rating is "Buy".

Price Target	$71.67
Price Target Difference	8.41%
Analyst Consensus	Buy
Analyst Count	12
Revenue Growth Forecast (5Y)	21.76%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AnaptysBio has an Altman Z-Score of 0.46 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.46
Piotroski F-Score	6